Nasopharyngeal cancer liver metastasis can be treated with immunotherapy. Nasopharyngeal cancer is a malignant tumor closely related to EBV (Epstein-Barr Virus) infection, and more than 70% of patients have locally advanced disease at the time of diagnosis. Recurrence and metastasis are the main reasons for the failure of nasopharyngeal cancer treatment. When nasopharyngeal cancer is combined with liver metastasis, it suggests that the disease is in advanced stage, and the treatment aims at improving the quality of life and prolonging the survival period of patients. Immunotherapy methods for nasopharyngeal cancer are divided into two categories: 1. active immunity that enhances the body’s ability to recognize and kill tumors: immunotherapeutic methods for EBV-positive nasopharyngeal carcinoma include relay cellular immunotherapy and tumor vaccine, which are currently under clinical research. 2. Represented by immune checkpoint inhibitors (ICIs): mainly including anti-programmed death receptor 1PD-1)/programmed death ligand 1 (PD-L1) therapy and anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy. There are studies on the salvage treatment of ICIs in recurrent or metastatic nasopharyngeal carcinoma that cannot be treated with radiotherapy and surgery. It is recommended to go to regular hospitals for comprehensive assessment of the condition, and it is necessary to choose the appropriate treatment plan according to the situation and follow the doctor’s instructions to actively cooperate with the treatment so as to avoid delaying the condition.